Quinapril

Angiotensin Converting Enzyme Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Quinapril is an ofp drug in the Angiotensin Converting Enzyme Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1991. Its mechanism of action is classified as Angiotensin-converting Enzyme Inhibitors. DrugCentral lists 2 molecular targets, including ACE and ACE. Recorded indications include Chronic heart failure and Hypertensive disorder.

• Approval status: ofp (first approved 1991 by the FDA).
• Drug class: Angiotensin Converting Enzyme Inhibitor.
• Mechanism of action: Angiotensin-converting Enzyme Inhibitors.
• Molecular targets: ACE and ACE (2 listed in DrugCentral).
• Indications: Chronic heart failure and Hypertensive disorder.
• ATC code: C09AA06 (ACE inhibitors, plain).
• Molecular formula: C25H30N2O5; molecular weight 438.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Chronic heart failure
• Hypertensive disorder

Off-label uses (5)

• Acute scleroderma renal crisis
• Atrial fibrillation
• Diabetic renal disease
• Diastolic heart failure
• Nondiabetic Proteinuric Nephropathy

Contraindications (35)

• Acute cerebrovascular insufficiency
• Acute pancreatitis
• Angioedema
• Anuria
• Azotemia
• Bone marrow depression
• Dehydration
• Diabetes mellitus
• Disease of liver
• Disorder of connective tissue
• Gout
• Hemodialysis with High-Flux Membrane
• Hepatic coma
• Hereditary angioneurotic edema
• Hypercalcemia
• Hypercholesterolemia
• Hyperkalemia
• Hyperparathyroidism
• Hyperuricemia
• Hypochloremic alkalosis
• Hypokalemia
• Hypomagnesemia
• Hyponatremia
• Hypovolemia
• Immunosuppression
• Kidney disease
• Low blood pressure
• Myocardial ischemia
• Neonatal hyperbilirubinemia
• Neutropenic disorder
• + 5 more

Mechanism & targets

• Mechanism of action (MoA): Angiotensin-converting Enzyme Inhibitors
• Established pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Angiotensin-converting enzyme	ACE	inhibitor	IC50 8.08
Angiotensin-converting enzyme	ACE	unknown	IC50 5.40

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1991-11-19	FDA	—	PFIZER PHARMS

ATC classification

ATC code	Therapeutic hierarchy
C09AA06	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, PLAIN › ACE inhibitors, plain
C09BA06	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors and diuretics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Sedation complication	1690.2
Creatinine renal clearance decreased	1606.9
Orthostatic hypotension	1450.5
Blood calcium decreased	1381.7
Sedation	1349.3
Cognitive disorder	1289.4
Balance disorder	1150.8
Depressed level of consciousness	957.5
Constipation	651.8
Fall	624.3
Mobility decreased	592.3
Hypotension	580.8

Chemical structure

• Molecular formula: C₂₅H₃₀N₂O₅
• Molecular weight: 438.52 g/mol
• CAS number: 85441-61-8
• InChIKey: JSDRRTOADPPCHY-HSQYWUDLSA-N
• PubChem CID: 107994

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Quinapril used for?

DrugCentral lists the following indications for Quinapril: Chronic heart failure and Hypertensive disorder.

How does Quinapril work?

Quinapril is classified as Angiotensin-converting Enzyme Inhibitors; its molecular targets in DrugCentral include ACE (inhibitor) and ACE.

When was Quinapril first approved?

Quinapril was first approved by the FDA in 1991.

What drug class does Quinapril belong to?

Quinapril is in the Angiotensin Converting Enzyme Inhibitor class.

What is the chemical formula of Quinapril?

Quinapril has the molecular formula C25H30N2O5 and a molecular weight of 438.52 g/mol.

Sources

• DrugCentral drug card 2340 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201011 — compound record and bioactivity
• PubChem CID 107994 — chemical identifiers
• DrugBank DB00881 — drug record
• FDA UNII 34SSX5LDE5 — substance identity
• DailyMed: FDA labels for Quinapril — current prescribing information (label search)
• UniProt P12821 (ACE) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.